Professor Xu Song was awarded a PhD from the Peking Union Medical College and a postdoctoral position at Yale University. He is professor at the Sichuan University and at the same time chief scientist of the National Key Research & Development Program, executive director of the Genetic Society of China, and president of the Genetic Society of Sichuan.
Xu Song has participated in many important projects, such as the National Key R&D Program of the Ministry of Science and Technology, the 973 Project, the Major New Drug Development Project, sub-projects of major NSFC (National Natural Science Foundation of China) projects, the Major Research Plan of the NSFC, surface projects of the NSFC, as well as the Priority Field Project of the Doctoral Program of the Ministry of Education.
As one of the pioneers in lncRNA research worldwide, he has been committed to studying lncRNA-protein interactions and their significance in tumor genesis and development including foundational research of the specific mechanism and effect of lncRNA which was published in a series of papers between 2002 and 2009. Based on extensive experience in lncRNA, a series of platform technologies for lncRNA drug patents have been developed.

Dr. Lihua Ding studied medicine for 8 years at Zhejiang University and Shanghai Jiao Tong University School of Medicine for his master's degree in medicine and also holds a MBA from the National University of Singapore. In his early years, he was doctor at a top tier hospital and entered the pharmaceutical industry in 1991.
Dr. Ding has more than 20 years of experience as a senior executive in the top 10 MNCs in China. He successively served as the Director of the Prescription Drug Division of Janssen, the Commercial General Manager of Abbott China, the General Manager of Fresenius-SSPC, and the core managing member of Asia Pacific.
Dr. Ding also has many years of experience with domestic innovative enterprises from market development to overall management. As General Manager he reorganized the mainland China team of Cheers Pharmaceutical and established the sales & marketing headquarters of Hisun Pharmaceutical. Furthermore, he established the business division of Eakan Pharmaceutical and served as their CEO. Later, he served as the Managing Director of ZongFar Pharmaceutical. In recent years, he served as the Co-CEO of LinkDoc, a medical big data company.
He is the first alumni tutor at Zhejiang University School of Medicine, the independent director of the listed Betta Pharmaceuticals, the senior expert consultant of Yidu Technology, the CEO Advisor of Vistage America, and the founder and Chief CEO Chair of MoHoney.
With his strong professional education background and years of experience in diversified matrix management, he is able to lead our team to establish new systems quickly, creating an added value for patients and society.

Professor Chong Qin was awarded a PhD in Pharmaceutical Chemistry from the Peking University and subsequently a postdoctoral position at the University of Michigan.
He is engaged in the research and development of small molecule protein degradation drugs for many years, publishing 16 articles in top international pharmaceutical journals that have been cited more than 600 times. Moreover, he participated in the development of oral androgen receptor (AR) inhibitors which entered Oncopia's pipeline and were acquired by Roivant later. In addition, he successfully developed the BET protein degradation agent with the strongest activity reported so far, which is 100-5000 times stronger than similar BET degradation agent.